Conmed
A global medical technology company that specializes in the development and sale of surgical and patient monitoring products and services.
- Healthcare
- medical devices
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $550m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 17 % | 3 % | 19 % | 5 % | 5 % | 5 % | 6 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 11 % | (4 %) | 15 % | 21 % | 20 % | 20 % | 21 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 6 % | (8 %) | 5 % | 10 % | 8 % | 9 % | 9 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 5 % | 4 % | 4 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Conmed Corporation was founded in 1970 by Eugene Corasanti, a visionary entrepreneur with a keen interest in advancing medical technology. The company initially focused on developing and manufacturing medical devices that would improve surgical outcomes and patient care. Corasanti's leadership and vision were instrumental in steering the company through its formative years.
In 1987, Conmed took a significant step forward by going public through an initial public offering on the NASDAQ exchange. This move not only provided the company with the capital needed to expand its operations but also increased its visibility in the competitive medical technology industry.
Over the years, Conmed has grown through strategic acquisitions and continuous innovation in surgical and patient monitoring products. These efforts have solidified its position as a key player in the global medical technology market.
Today, Conmed continues to build on its legacy of innovation, focusing on developing cutting-edge medical devices that enhance the quality of healthcare worldwide. The company's journey from a small startup to a publicly traded corporation is a testament to its enduring commitment to improving medical outcomes through technology.
Tech stack
Investments by Conmed
Edit
